Cargando…

Viral Vector-Based Melanoma Gene Therapy

Gene therapy applications of oncolytic viruses represent an attractive alternative for cancer treatment. A broad range of oncolytic viruses, including adenoviruses, adeno-associated viruses, alphaviruses, herpes simplex viruses, retroviruses, lentiviruses, rhabdoviruses, reoviruses, measles virus, N...

Descripción completa

Detalles Bibliográficos
Autores principales: Hromic-Jahjefendic, Altijana, Lundstrom, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148454/
https://www.ncbi.nlm.nih.gov/pubmed/32187995
http://dx.doi.org/10.3390/biomedicines8030060
_version_ 1783520596250853376
author Hromic-Jahjefendic, Altijana
Lundstrom, Kenneth
author_facet Hromic-Jahjefendic, Altijana
Lundstrom, Kenneth
author_sort Hromic-Jahjefendic, Altijana
collection PubMed
description Gene therapy applications of oncolytic viruses represent an attractive alternative for cancer treatment. A broad range of oncolytic viruses, including adenoviruses, adeno-associated viruses, alphaviruses, herpes simplex viruses, retroviruses, lentiviruses, rhabdoviruses, reoviruses, measles virus, Newcastle disease virus, picornaviruses and poxviruses, have been used in diverse preclinical and clinical studies for the treatment of various diseases, including colon, head-and-neck, prostate and breast cancer as well as squamous cell carcinoma and glioma. The majority of studies have focused on immunotherapy and several drugs based on viral vectors have been approved. However, gene therapy for malignant melanoma based on viral vectors has not been utilized to its full potential yet. This review represents a summary of the achievements of preclinical and clinical studies using viral vectors, with the focus on malignant melanoma.
format Online
Article
Text
id pubmed-7148454
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71484542020-04-21 Viral Vector-Based Melanoma Gene Therapy Hromic-Jahjefendic, Altijana Lundstrom, Kenneth Biomedicines Review Gene therapy applications of oncolytic viruses represent an attractive alternative for cancer treatment. A broad range of oncolytic viruses, including adenoviruses, adeno-associated viruses, alphaviruses, herpes simplex viruses, retroviruses, lentiviruses, rhabdoviruses, reoviruses, measles virus, Newcastle disease virus, picornaviruses and poxviruses, have been used in diverse preclinical and clinical studies for the treatment of various diseases, including colon, head-and-neck, prostate and breast cancer as well as squamous cell carcinoma and glioma. The majority of studies have focused on immunotherapy and several drugs based on viral vectors have been approved. However, gene therapy for malignant melanoma based on viral vectors has not been utilized to its full potential yet. This review represents a summary of the achievements of preclinical and clinical studies using viral vectors, with the focus on malignant melanoma. MDPI 2020-03-16 /pmc/articles/PMC7148454/ /pubmed/32187995 http://dx.doi.org/10.3390/biomedicines8030060 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hromic-Jahjefendic, Altijana
Lundstrom, Kenneth
Viral Vector-Based Melanoma Gene Therapy
title Viral Vector-Based Melanoma Gene Therapy
title_full Viral Vector-Based Melanoma Gene Therapy
title_fullStr Viral Vector-Based Melanoma Gene Therapy
title_full_unstemmed Viral Vector-Based Melanoma Gene Therapy
title_short Viral Vector-Based Melanoma Gene Therapy
title_sort viral vector-based melanoma gene therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148454/
https://www.ncbi.nlm.nih.gov/pubmed/32187995
http://dx.doi.org/10.3390/biomedicines8030060
work_keys_str_mv AT hromicjahjefendicaltijana viralvectorbasedmelanomagenetherapy
AT lundstromkenneth viralvectorbasedmelanomagenetherapy